Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study - Publication - Bridge of Knowledge

Search

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Abstract

Citations

  • 3 5 4

    CrossRef

  • 0

    Web of Science

  • 3 7 7

    Scopus

Authors (23)

  • Photo of  Martin Dreyling

    Martin Dreyling

  • Photo of MD, PhD, Prof Wojciech Jurczak

    Wojciech Jurczak MD, PhD, Prof

  • Photo of  Mats Jerkeman

    Mats Jerkeman

  • Photo of  Rodrigo Silva

    Rodrigo Silva

  • Photo of  Chiara Rusconi

    Chiara Rusconi

  • Photo of  Marek Trneny

    Marek Trneny

  • Photo of  Fritz Offner

    Fritz Offner

  • Photo of  Dolores Caballero

    Dolores Caballero

  • Photo of  Cristina Joao

    Cristina Joao

  • Photo of  Mathias Witzens-Harig

    Mathias Witzens-Harig

  • Photo of  Georg Hess

    Georg Hess

  • Photo of  Isabelle Bence-Bruckler

    Isabelle Bence-Bruckler

  • Photo of  Seok-Goo Cho

    Seok-Goo Cho

  • Photo of  John Bothos

    John Bothos

  • Photo of  Jenna Goldberg

    Jenna Goldberg

  • Photo of  Christopher Enny

    Christopher Enny

  • Photo of  Shana Traina

    Shana Traina

  • Photo of  Sriram Balasubramanian

    Sriram Balasubramanian

  • Photo of  Nibedita Bandyopadhyay

    Nibedita Bandyopadhyay

  • Photo of  Steven Sun

    Steven Sun

  • Photo of  Jessica Vermeulen

    Jessica Vermeulen

  • Photo of  Aleksandra Rizo

    Aleksandra Rizo

  • Photo of  Simon Rule

    Simon Rule

Cite as

Full text

full text is not available in portal

Details

Category:
Magazine publication
Type:
Magazine publication
Published in:
LANCET no. 387, edition 10020, pages 770 - 778,
ISSN: 0140-6736
ISSN:
0140-6736
Publication year:
2016
DOI:
Digital Object Identifier (open in new tab) 10.1016/s0140-6736(15)00667-4
Verified by:
No verification

seen 55 times

Meta Tags